Pruritus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major pruritus markets reached a value of US$ 6.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 7.8 Billion by 2034, exhibiting a growth rate (CAGR) of 2.42% during 2024-2034.
The pruritus market has been comprehensively analyzed in IMARC's new report titled "Pruritus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pruritus, also known as itching, refers to an unpleasant sensation or feeling on the skin that provokes the desire to scratch. The condition can be irritating or painful and could be localized to one part of the body or extend to numerous areas. Pruritus can range in severity from mild to severe, and it can be acute or chronic. Some of the common symptoms associated with the ailment include itching, inflamed skin, scratch marks, spots, blisters, dry and cracked skin, thick and leathery patches, localized pain at the affected site, etc. Individuals suffering from pruritus may also experience skin discoloration, a rash, bleeding, and large, fluid-filled bumps on the impacted skin region. The diagnosis of this disorder is generally based on the patient's underlying indications, medical history, and physical examination. Allergy tests, blood workups, and various imaging studies, such as X-rays, are also utilized to detect the cause of symptoms and confirm a diagnosis. Additionally, the healthcare provider may perform a skin biopsy, which involves taking a tiny sample of the affected region and investigating it under a microscope.
The increasing cases of skin disorders, such as eczema, psoriasis, hives, etc., coupled with the rising prevalence of fungal infections like athlete's foot or jock itch are primarily driving the pruritus market. In addition to this, the expanding geriatric population, who are prone to reduced production of sebum, skin-surface lipids, and perfusion, causing dry aging skin, is also bolstering the market growth. Moreover, the escalating utilization of antihistamines, including hydroxyzine and diphenhydramine, for relieving itch and inflammation by blocking histamine activity is creating a positive outlook for the market. Apart from this, the inflating usage of transcutaneous electrical nerve stimulation therapy, which applies electrical impulses that can reduce the pain signals going to the spinal cord and brain, thereby helping relieve aching and relax muscles, is further propelling the market growth. Additionally, the emerging popularity of topical corticosteroids, since they are effective in managing symptoms like redness, itching, swelling, and skin discomfort, is acting as another significant growth-inducing factor. Besides this, the widespread adoption of ultraviolet phototherapy, which decreases the growth of the skin cells to treat underlying inflammation and improve quality of life, is expected to drive the pruritus market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the pruritus market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for pruritus and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pruritus market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the pruritus market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the pruritus market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current pruritus marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the pruritus market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the pruritus market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the pruritus market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of pruritus across the seven major markets?
What is the number of prevalent cases (2018-2034) of pruritus by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of pruritus by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with pruritus across the seven major markets?
What is the size of the pruritus patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of pruritus?
What will be the growth rate of patients across the seven major markets?
Pruritus: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for pruritus drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pruritus market?
What are the key regulatory events related to the pruritus market?
What is the structure of clinical trial landscape by status related to the pruritus market?
What is the structure of clinical trial landscape by phase related to the pruritus market?
What is the structure of clinical trial landscape by route of administration related to the pruritus market?
The pruritus market has been comprehensively analyzed in IMARC's new report titled "Pruritus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pruritus, also known as itching, refers to an unpleasant sensation or feeling on the skin that provokes the desire to scratch. The condition can be irritating or painful and could be localized to one part of the body or extend to numerous areas. Pruritus can range in severity from mild to severe, and it can be acute or chronic. Some of the common symptoms associated with the ailment include itching, inflamed skin, scratch marks, spots, blisters, dry and cracked skin, thick and leathery patches, localized pain at the affected site, etc. Individuals suffering from pruritus may also experience skin discoloration, a rash, bleeding, and large, fluid-filled bumps on the impacted skin region. The diagnosis of this disorder is generally based on the patient's underlying indications, medical history, and physical examination. Allergy tests, blood workups, and various imaging studies, such as X-rays, are also utilized to detect the cause of symptoms and confirm a diagnosis. Additionally, the healthcare provider may perform a skin biopsy, which involves taking a tiny sample of the affected region and investigating it under a microscope.
The increasing cases of skin disorders, such as eczema, psoriasis, hives, etc., coupled with the rising prevalence of fungal infections like athlete's foot or jock itch are primarily driving the pruritus market. In addition to this, the expanding geriatric population, who are prone to reduced production of sebum, skin-surface lipids, and perfusion, causing dry aging skin, is also bolstering the market growth. Moreover, the escalating utilization of antihistamines, including hydroxyzine and diphenhydramine, for relieving itch and inflammation by blocking histamine activity is creating a positive outlook for the market. Apart from this, the inflating usage of transcutaneous electrical nerve stimulation therapy, which applies electrical impulses that can reduce the pain signals going to the spinal cord and brain, thereby helping relieve aching and relax muscles, is further propelling the market growth. Additionally, the emerging popularity of topical corticosteroids, since they are effective in managing symptoms like redness, itching, swelling, and skin discomfort, is acting as another significant growth-inducing factor. Besides this, the widespread adoption of ultraviolet phototherapy, which decreases the growth of the skin cells to treat underlying inflammation and improve quality of life, is expected to drive the pruritus market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the pruritus market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for pruritus and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pruritus market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the pruritus market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the pruritus market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current pruritus marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the pruritus market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the pruritus market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the pruritus market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of pruritus across the seven major markets?
What is the number of prevalent cases (2018-2034) of pruritus by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of pruritus by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with pruritus across the seven major markets?
What is the size of the pruritus patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of pruritus?
What will be the growth rate of patients across the seven major markets?
Pruritus: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for pruritus drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pruritus market?
What are the key regulatory events related to the pruritus market?
What is the structure of clinical trial landscape by status related to the pruritus market?
What is the structure of clinical trial landscape by phase related to the pruritus market?
What is the structure of clinical trial landscape by route of administration related to the pruritus market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PRURITUS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034?)
4.4 Market Overview (2018-2023) and Forecast (2024-2034?)
4.5 Competitive Intelligence
5 PRURITUS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PRURITUS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034?)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034?)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034?)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034?)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034?)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034?)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034?)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034?)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 PRURITUS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PRURITUS - UNMET NEEDS
10 PRURITUS - KEY ENDPOINTS OF TREATMENT
11 PRURITUS - MARKETED PRODUCTS
11.1 List of Pruritus Marketed Drugs Across the Top 7 Markets
11.1.1 Korsuva (Difelikefalin) - Cara Therapeutics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Livmarli (Maralixibat) - Mirum Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Bylvay (Odevixibat) - Albireo Pharma
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 PRURITUS - PIPELINE DRUGS
12.1 List of Pruritus Pipeline Drugs Across the Top 7 Markets
12.1.1 Nemolizumab - Chugai Pharmaceutical
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 EP547 - Escient Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Dupilumab - Regeneron/Sanofi
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Linerixibat - GlaxoSmithKline
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 MC2-25 - MC2 Therapeutics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PRURITUS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PRURITUS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PRURITUS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Pruritus - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034?)
15.2.2 Pruritus - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034?)
15.3 Market Scenario - United States
15.3.1 Pruritus - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034?)
15.3.2 Pruritus - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034?)
15.3.3 Pruritus - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Pruritus - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034?)
15.4.2 Pruritus - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034?)
15.4.3 Pruritus - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Pruritus - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034?)
15.5.2 Pruritus - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034?)
15.5.3 Pruritus - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Pruritus - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034?)
15.6.2 Pruritus - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034?)
15.6.3 Pruritus - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Pruritus - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034?)
15.7.2 Pruritus - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034?)
15.7.3 Pruritus - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Pruritus - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034?)
15.8.2 Pruritus - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034?)
15.8.3 Pruritus - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Pruritus - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034?)
15.9.2 Pruritus - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034?)
15.9.3 Pruritus - Access and Reimbursement Overview
16 PRURITUS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PRURITUS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PRURITUS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PRURITUS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034?)
4.4 Market Overview (2018-2023) and Forecast (2024-2034?)
4.5 Competitive Intelligence
5 PRURITUS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PRURITUS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034?)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034?)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034?)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034?)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034?)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034?)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034?)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034?)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 PRURITUS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PRURITUS - UNMET NEEDS
10 PRURITUS - KEY ENDPOINTS OF TREATMENT
11 PRURITUS - MARKETED PRODUCTS
11.1 List of Pruritus Marketed Drugs Across the Top 7 Markets
11.1.1 Korsuva (Difelikefalin) - Cara Therapeutics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Livmarli (Maralixibat) - Mirum Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Bylvay (Odevixibat) - Albireo Pharma
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 PRURITUS - PIPELINE DRUGS
12.1 List of Pruritus Pipeline Drugs Across the Top 7 Markets
12.1.1 Nemolizumab - Chugai Pharmaceutical
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 EP547 - Escient Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Dupilumab - Regeneron/Sanofi
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Linerixibat - GlaxoSmithKline
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 MC2-25 - MC2 Therapeutics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PRURITUS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PRURITUS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PRURITUS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Pruritus - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034?)
15.2.2 Pruritus - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034?)
15.3 Market Scenario - United States
15.3.1 Pruritus - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034?)
15.3.2 Pruritus - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034?)
15.3.3 Pruritus - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Pruritus - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034?)
15.4.2 Pruritus - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034?)
15.4.3 Pruritus - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Pruritus - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034?)
15.5.2 Pruritus - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034?)
15.5.3 Pruritus - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Pruritus - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034?)
15.6.2 Pruritus - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034?)
15.6.3 Pruritus - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Pruritus - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034?)
15.7.2 Pruritus - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034?)
15.7.3 Pruritus - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Pruritus - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034?)
15.8.2 Pruritus - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034?)
15.8.3 Pruritus - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Pruritus - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034?)
15.9.2 Pruritus - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034?)
15.9.3 Pruritus - Access and Reimbursement Overview
16 PRURITUS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PRURITUS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PRURITUS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
